These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 10499904

  • 1. Thrombogenicity of prothrombin complex concentrates.
    Köhler M.
    Thromb Res; 1999 Aug 15; 95(4 Suppl 1):S13-7. PubMed ID: 10499904
    [Abstract] [Full Text] [Related]

  • 2. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.
    Köhler M, Hellstern P, Lechler E, Uberfuhr P, Müller-Berghaus G.
    Thromb Haemost; 1998 Sep 15; 80(3):399-402. PubMed ID: 9759617
    [Abstract] [Full Text] [Related]

  • 3. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates.
    Dusel CH, Grundmann C, Eich S, Seitz R, König H.
    Blood Coagul Fibrinolysis; 2004 Jul 15; 15(5):405-11. PubMed ID: 15205589
    [Abstract] [Full Text] [Related]

  • 4. Intravascular coagulation with use of human prothrombin complex concentrates.
    Cederbaum AI, Blatt PM, Roberts HR.
    Ann Intern Med; 1976 Jun 15; 84(6):683-7. PubMed ID: 937880
    [Abstract] [Full Text] [Related]

  • 5. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency.
    Hellstern P.
    Thromb Res; 1999 Aug 15; 95(4 Suppl 1):S7-12. PubMed ID: 10499903
    [Abstract] [Full Text] [Related]

  • 6. Prothrombin Complex Concentrate-induced Disseminated Intravascular Coagulation Can Be Prevented by Coadministering Antithrombin in a Porcine Trauma Model.
    Grottke O, Honickel M, Braunschweig T, Reichel A, Schöchl H, Rossaint R.
    Anesthesiology; 2019 Sep 15; 131(3):543-554. PubMed ID: 31180918
    [Abstract] [Full Text] [Related]

  • 7. Rational, high quality laboratory monitoring before, during, and after infusion of prothrombin complex concentrates.
    Halbmayer WM.
    Thromb Res; 1999 Aug 15; 95(4 Suppl 1):S25-30. PubMed ID: 10499906
    [Abstract] [Full Text] [Related]

  • 8. Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.
    Hampton KK, Makris M, Kitchen S, Preston FE.
    Blood Coagul Fibrinolysis; 1991 Oct 15; 2(5):637-41. PubMed ID: 1782333
    [Abstract] [Full Text] [Related]

  • 9. Prothrombin complex concentrates for clinical use.
    Chandra S, Brummelhuis HG.
    Vox Sang; 1981 Oct 15; 41(5-6):257-73. PubMed ID: 6798760
    [Abstract] [Full Text] [Related]

  • 10. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.
    Takeyama M, Sakurai Y, Shima M, Matsumoto T, Nogami K, Tanaka I, Takeda T, Giddings JC, Yoshioka A.
    Blood Coagul Fibrinolysis; 2007 Jan 15; 18(1):1-7. PubMed ID: 17179819
    [Abstract] [Full Text] [Related]

  • 11. Thrombogenic materials in prothrombin complex concentrates.
    Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR.
    Ann Intern Med; 1974 Dec 15; 81(6):766-70. PubMed ID: 4433081
    [No Abstract] [Full Text] [Related]

  • 12. Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.
    Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R.
    Crit Care; 2011 Dec 15; 15(1):201. PubMed ID: 21345266
    [Abstract] [Full Text] [Related]

  • 13. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary.
    Hellstern P, Halbmayer WM, Köhler M, Seitz R, Müller-Berghaus G.
    Thromb Res; 1999 Aug 15; 95(4 Suppl 1):S3-6. PubMed ID: 10499902
    [No Abstract] [Full Text] [Related]

  • 14. [Quality control of prothrombin complex preparations: in vivo and in vitro findings].
    Köhler M, Habauer G, Miyashita C, Braun B, Mörsdorf S, Pindur G, Heiden M, Rose S, Ernert P.
    Beitr Infusionsther; 1990 Aug 15; 26():186-9. PubMed ID: 1703826
    [Abstract] [Full Text] [Related]

  • 15. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF, Drummond O, MacGregor IR.
    Thromb Haemost; 1992 Nov 10; 68(5):511-5. PubMed ID: 1455396
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity of the fibrinogen clotting time: an in vitro test of potential thrombogenicity.
    Feldman PA, McGrath S, Evans H.
    Vox Sang; 1994 Nov 10; 66(1):1-7. PubMed ID: 8146976
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB.
    Haemophilia; 2005 Nov 10; 11(6):583-8. PubMed ID: 16236107
    [Abstract] [Full Text] [Related]

  • 18. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham EG, Lowe GD, Rumley A, Ludlam CA.
    Thromb Haemost; 1996 Jul 10; 76(1):23-8. PubMed ID: 8819246
    [Abstract] [Full Text] [Related]

  • 19. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM.
    Semin Hematol; 1991 Jul 10; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract] [Full Text] [Related]

  • 20. Virus safety of prothrombin complex concentrates and factor IX concentrates.
    Seitz R, Dodt J.
    Thromb Res; 1999 Aug 15; 95(4 Suppl 1):S19-23. PubMed ID: 10499905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.